Aarti Pharmalabs Ltd
Aarti Pharmalabs Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
CDMO business is expected to exceed earlier 30%-40% growth guidance in FY '26, with substantial sales in H2 and next year contributing to overall revenue growth. FY '26 EBITDA growth guidance revised to 8%-12% year-on-year, despite challenges (Page 4).
From Aarti Pharmalabs Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- CDMO business is expected to exceed earlier 30%-40% growth guidance in FY '26, with substantial sales in H2 and next year contributing to overall revenue growth.
- New molecules moving from development to commercial phase will drive sales, with larger growth anticipated in FY '27 and beyond.
- API business to normalize and ramp up in H2 FY '26 after inventory corrections and product mix optimization, including oncology and steroid APIs, with major launches in FY '27 and FY '28.
- Atali plant will become fully operational in 2-3 quarters, boosting Intermediate and CDMO business revenue from FY '27 onward.
- Xanthine capacity expansion to 9,000 tons/year by end of FY '26, with gradual ramp-up over 2-3 years expected to capture ~25% market share.
- Long-term target of INR 1,000 crore revenue from CDMO side in 2-3 years considered achievable.
- Overall EBITDA growth guidance is 8%-12% for FY '26, with a longer-term goal of 15%-20% EBITDA growth over 3 years.
Profitability & Margins
See what Aarti Pharmalabs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Atali plant: INR 450 crore CAPEX, inaugurated in September 2025, started operations with trial batches; expected to be fully operational in 2-3 quarters (by FY '27) to contribute meaningfully to revenue.
- Xanthine expansion: Capacity increased from 5,000 to 9,000 metric tons (annual installed capacity) by end of FY '26; expansion is brownfield with phased operationalization.
- Facility upgrades: Focus on debottlenecking and standardizing production, including at Ganesh Polychem to improve cost efficiency and profitability.
- Site shifting plan: Future plan to shift Dombivli site within the year as part of strategic operational improvements.
- Ongoing R&D and capacity capitalization: Some projects still under capital work-in-progress (WIP), with more capitalization expected towards year-end.
- Expansion supports future growth, especially in Intermediate and CDMO-CMO business segments.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Aarti Pharmalabs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The CDMO-CMO segment currently has 59 active projects, with 39 in the commercial stage and 20 under various stages of development at the customer's end.
- The company is working with 21 customers in this segment and is on track to achieve and exceed the earlier estimated sales target of 30% to 40% Y-o-Y growth.
- Management is actively participating in several RFPs (Requests for Proposals) to increase the CDMO project funnel, including expanding geographical presence in Europe and North America to boost business development.
- New product commercializations and approvals over recent quarters have led to enhanced visibility and long-term potential order book growth.
- Expansion and capacity debottlenecking, particularly in the Xanthine segment and Atali facility, indicate readiness to fulfill growing orders, with full operational capacity expected in 2-3 quarters for Atali and Xanthine capacity expected to ramp up to 9,000 MT by year-end.
Aarti Pharmalabs Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹583 Cr, net profit ₹61 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Aarti Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Alivus Life (Q2 FY26)
Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores. Key concall takeaways from Alivus Life's Q2 FY26 earnings call — and how it ranks against sector…
- Solara Active Pharma Sciences Ltd (Q2 FY26)
Current facility capacity utilization is about 70%, with capacity available to serve new customers. Key concall takeaways from Solara Active's Q2 FY26 earnings…
- Sun Pharma.Inds. (Q2 FY26)
India formulation sales grew 11% in Q2, outpacing Indian Pharmaceutical Market (IPM) growth mainly driven by volume and new product launches. Key concall…
- Zydus Lifesci. (Q2 FY26)
Branded formulations in India growing ahead of market at 9% YoY, driven by chronic, cardiology, gynecology, and oncology therapies. Key concall takeaways from…
Frequently Asked Questions
What were Aarti Pharmalabs Ltd Q2 FY26 results?
CDMO business is expected to exceed earlier 30%-40% growth guidance in FY '26, with substantial sales in H2 and next year contributing to overall revenue growth. FY '26 EBITDA growth guidance revised to 8%-12% year-on-year, despite challenges (Page 4).
What is Aarti Pharmalabs Ltd share price analysis?
Aarti Pharmalabs Ltd currently shows a neutral. The stock trades at a P/E of 35.0 with a market cap of ₹6,193 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aarti Pharmalabs Ltd planning capital expenditure?
Atali plant: INR 450 crore CAPEX, inaugurated in September 2025, started operations with trial batches; expected to be fully operational in 2-3 quarters (by FY '27) to contribute meaningfully to revenue.
Keep Aarti Pharmalabs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.